Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Multiple Sclerosis and Related Disorders

• Publication date

  2018-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.MSARD.2018.10.105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Ocrelizumab for multiple sclerosis.

  2022cites this paper
• Setrvání na léčbě ocrelizumabem a lokální zkušenosti

  2021cites this paper
• The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

  2020cites this paper
• Долгосрочные результаты терапии рассеянного склероза окрелизумабом: клиническая и МРТ-эффективность и профиль безопасности

  2019cites this paper
• Ocrelizumab, clinical aktivity and progression - long-term data

  2019cites this paper
• Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile

  2019cites this paper
• Ocrelizumab , klinická aktivita a progrese – dlouhodobá data MUDr

  2019cites this paper
• Therapies for multiple sclerosis targeting B cells

  2019cites this paper
• Ocrelizumab for the treatment of multiple sclerosis

  2018cites this paper